Acasti Pharma Inc. reported earnings results for the full year ended March 31, 2024. For the full year, the company reported net loss was USD 12.85 million compared to USD 42.43 million a year ago. Basic loss per share from continuing operations was USD 1.35 compared to USD 5.71 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.96 USD | -4.52% |
|
-10.09% | +2.42% |
Jun. 21 | Acasti Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
May. 28 | Acasti Pharma Inc. to Attend BIO International Convention 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.42% | 27.82M | |
+54.61% | 811B | |
+43.70% | 640B | |
-6.33% | 353B | |
+20.62% | 333B | |
+10.44% | 302B | |
+17.53% | 246B | |
+2.54% | 225B | |
+12.61% | 218B | |
+8.61% | 168B |
- Stock Market
- Equities
- ACST Stock
- News Acasti Pharma Inc.
- Acasti Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024